Literature DB >> 6544116

Effects of sterols on the therapeutic efficacy of liposomal amphotericin B in murine candidiasis.

G Lopez-Berestein, R Mehta, R Hopfer, K Mehta, E M Hersh, R Juliano.   

Abstract

Incorporation of amphotericin B (AMP-B) into phospholipid vesicles (liposomes) has been shown previously to decrease AMP-B toxicity while retaining the antifungal efficacy of the drug. In this report, the role of sterols in the formulation of liposomes as well as in their effectiveness in the treatment of murine candidiasis have been investigated. The presence of ergosterol or cholesterol at different lipid ratios did not augment the encapsulation efficiency of AMP-B as compared with vesicles containing phospholipids alone. There was no significant difference in the survival time of mice infected with Candida albicans treated with sterol-containing vesicles compared with those treated with sterol-free vesicles. These findings suggest that the sterol-free liposomes might be of advantage for delivering AMP-B because of its simple formulation, lack of toxicity, and ease of preparation.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6544116     DOI: 10.1089/cdd.1983.1.37

Source DB:  PubMed          Journal:  Cancer Drug Deliv        ISSN: 0732-9482


  17 in total

Review 1.  Clinical Translation of Nanomedicine.

Authors:  Yuanzeng Min; Joseph M Caster; Michael J Eblan; Andrew Z Wang
Journal:  Chem Rev       Date:  2015-06-19       Impact factor: 60.622

2.  Synergistic antifungal activity and reduced toxicity of liposomal amphotericin B combined with gramicidin S or NF.

Authors:  R L Hopfer; R Mehta; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

Review 3.  Liposomes as carriers of antimicrobial agents.

Authors:  G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1987-05       Impact factor: 5.191

Review 4.  Carrier effects on biological activity of amphotericin B.

Authors:  J Brajtburg; J Bolard
Journal:  Clin Microbiol Rev       Date:  1996-10       Impact factor: 26.132

5.  In vitro antifungal activities of amphotericin B and liposome-encapsulated amphotericin B.

Authors:  R L Hopfer; K Mills; R Mehta; G Lopez-Berestein; V Fainstein; R L Juliano
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

6.  Prophylaxis of Candida albicans infection in neutropenic mice with liposome-encapsulated amphotericin B.

Authors:  G Lopez-Berestein; R L Hopfer; R Mehta; K Mehta; E M Hersh; R L Juliano
Journal:  Antimicrob Agents Chemother       Date:  1984-03       Impact factor: 5.191

7.  Formulation, toxicity, and antifungal activity in vitro of liposome-encapsulated nystatin as therapeutic agent for systemic candidiasis.

Authors:  R T Mehta; R L Hopfer; L A Gunner; R L Juliano; G Lopez-Berestein
Journal:  Antimicrob Agents Chemother       Date:  1987-12       Impact factor: 5.191

8.  Therapeutic evaluation of free and liposome-encapsulated amphotericin B in the treatment of systemic candidiasis in mice.

Authors:  J A Gondal; R P Swartz; A Rahman
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

Review 9.  Liposomes and nanotechnology in drug development: focus on ocular targets.

Authors:  Miki Honda; Tomohiro Asai; Naoto Oku; Yoshihiko Araki; Minoru Tanaka; Nobuyuki Ebihara
Journal:  Int J Nanomedicine       Date:  2013-02-14

Review 10.  Optimizing efficacy of Amphotericin B through nanomodification.

Authors:  Gillian Barratt; Stéphane Bretagne
Journal:  Int J Nanomedicine       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.